Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4927-4940

  Wu, Rongfeng ^a   Zhou, Weidong ^a,b   Chen, Shuo ^b   Shi, Yan ^a   Su, Lin ^b   Zhu, Maobi ^b   Chen, Qionghua ^b   Chen, Qingxi ^a  

^a XIAMEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15S LIPOXYGENASE 2; GELATINASE B; INTERLEUKIN 1BETA; LIPOXIN A; LIPOXYGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG; ALOX15B PROTEIN, HUMAN; ARACHIDONATE 15 LIPOXYGENASE; CYTOKINE; LIPOXIN; LIPOXIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DNA REPLICATION; DOWN REGULATION; ENDOMETRIOSIS; ENDOMETRIOTIC STROMAL CELL; ENZYME ACTIVITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA INTERFERENCE; STROMA CELL; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; ENDOMETRIUM; FEMALE; GENE SILENCING; GENETICS; HUMAN; METABOLISM;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; CELLS, CULTURED; CYTOKINES; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; GENE SILENCING; HUMANS; LIPOXINS; MATRIX METALLOPROTEINASE 9; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, LIPOXIN; STROMAL CELLS;

EID: 84918817969     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12816     Document Type: Article

References (46)

1. Agarwal S, Achari C, Praveen D, Roy KR, Reddy GV, Reddanna P (2009). Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pat hways. Exp Dermatol 18: 939-946.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol. 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol. 170: 1797-1862.
4. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C (2009). Lipoxin A4: anti-inflammatory and anti-Angiogenic impact on endothelial cells. J Immunol 182: 3819-3826.
5. Bonnans C, Fukunaga K, Levy MA, Levy BD (2006). Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. Am J Pathol 168: 1064-1072.
6. Borghese B, Gayet V, Chiche JD, Vernerey D, de Ziegler D, Bonaiti-Pellie C et al. (2009). Absence of association between a functional polymorphism of ALOX15 gene and infertility in endometriosis. Fertil Steril 91 (4 Suppl.): 1414-1416.
7. Canny GO, Lessey BA (2013). The role of lipoxin A4 in endometrial biology and endometriosis. Mucosal Immunol 6: 439-450.
8. Cezar-De-Mello PF, Vieira AM, Nascimento-Silva V, Villela CG, Barja-Fidalgo C , Fierro IM (2008). ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 153: 956-965.
9. Chen QH , Zhou WD, Pu DM, Huang QS, Li T, Chen QX (2010a). 15-Epi-lipoxin A4 inhibits the progression of endometriosis in a murine model. Fertil Steril 93: 1440-1447.
10. Chen QH, Zhou WD, Su ZY, Hu ang QS, Jiang JN, Chen QX (2010b). Change of proinflammatory cytokines follows certain patterns after induction of endometriosis in a mouse model. Fertil Steril 93: 1448-1454.
11. Dziunycz P, Milewski L, Ra domski D, Barcz E, Kaminski P, Roszkowski PI et al. (2009). Elevated ghrelin levels in the peritoneal fluid of patients with endometriosis: associations with vascular endothelial growth factor (VEGF) and inflammatory cytokines. Fertil Steril 92: 1844-1849.
12. Giudice LC, Kao LC (2004). Endometriosis. Lancet 364: 1789-1799.
13. Gu L,Tseng S,Horner RM,Tam C,Loda M,Rollins BJ 2000). Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1 Nature 404 407-411.
14. Hao H, Liu M, Wu P, Cai L, Tang K, Yi P et al. (2011). Lipoxin A4 and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. Cancer Lett 309: 85-94.
15. Hapanga ma DK, Turner MA, Drury JA, Quenby S, Hart A, Maddick M et al. (2009). Sustained replication in endometrium of women with endometriosis occurs without evoking a DNA damage response. Hum Reprod 24: 687-696.
16. Hsi LC, Wilson LC, Eling TE (2002). Opposing effects of 15-lipoxygenase-1 and-2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-Activated receptor gamma. J Biol Chem 277: 40 549-40556.
17. Janakiram NB, Mohammed A, Rao CV (2011). Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev 30: 507-523.
18. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R et al. (2010). Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107: 1660-1665.
19. Lin SC, Wang CC, Wu MH, Yang SH, Li YH, Tsai SJ (2012). Hypoxia-induced microRNA-20a expression increases ERK phosphorylation and angiogenic gene expression in endometriotic stromal cells. J Clin Endocrinol Metab 97: 1515-15 23.
20. Macdonald LJ, Boddy SC, Denison FC, Sales KJ, Jabbour HN (2011). A role for lipoxin A4 as an anti-inflammatory mediator in the human endometrium. Reproduction 142: 345-352.
21. Maderna P, Godson C (2009). Lipoxins: resolutionary road. Br J Pharmacol 158: 947-959.
22. McMahon B, Mitchell S, Brady HR, Godson C (2001). Lipoxins: revelations on resolution. Trends Pharmacol Sci 22: 391-395.
23. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M et al. (2008). Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res 14: 6525-6530.
24. Moldovan GL, Pfander B, Jentsch S (2007). PCNA, the maestro of the replication fork. Cell 129: 665-679.
25. Motohashi E, Kawauchi H, Endo H, Kondo H, Kitasato H, Kuramoto H et al. (2005). Regulatory expression of lipoxin A4 receptor in physiologically estrus cycle and pathologically endometriosis. Biomed Pharmacother 59: 330-338.
26. Noyes RW, Hertig AT, Rock J (1975). Dating the endometrial biopsy. Am J Obstet Gynecol 122: 262-263.
27. Ono K, Han J (2000). The p38 signal transduction pathway: activation and function. Cell Signal 12: 1-13.
28. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
29. Podgaec S, Abrao MS, Dias JA Jr., Rizzo LV, de Oliveira RM, Baracat EC (2007). Endometriosis: an inflammatory disease with a Th2 immune response component. Hum Reprod 22: 1373-1379.
30. Robboy SJ, Bean SM (2010). Pathogenesis of endometriosis. Reprod Biomed Online 21: 4-5.
31. Russell R, Gori I, Pellegrini C, Kumar R, Achtari C, Canny GO (2011). Lipoxin A4 is a novel estrogen receptor modulator. FASEB J 25: 4326-4337.
32. Schmittgen TD, Livak KJ (2008). Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3: 1101-1108.
33. Selam B, Kayisli UA, Akbas GE, Basar M, Arici A (2006). Regulation of FAS ligand expression by chemokine ligand 2 in human endometrial cells. Biol Reprod 75: 203-209.
34. Serhan CN,Chiang N 2008a Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus Br J Pharmacol 153 (Suppl. 1 S200-S215
35. Serhan CN, Chiang N, Van Dyke TE (2008b ). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8: 349-361.
36. Seval Y, Cakmak H, Kayisli UA, Arici A (2006). Estrogen-mediated regulation of p38 mitogen-Activated protein kinase in human endometrium. J Clin Endocrinol Metab 91: 2349-2357.
37. Tang Y, Wang MT, Chen Y , Yang D, Che M, Honn KV et al. (2009). Downregulation of vascular endothelial growth factor and induction of tumor dormancy by 15-lipoxygenase-2 in prostate cancer. Int J Cancer 124: 1545-1551.
38. Ulu kus M, Ulukus EC, Seval Y, Zheng W, Arici A (2005). Expression of interleukin-8 receptors in endometriosis. Hum Reprod 20: 794-801.
39. Umezawa M, Sakata C, Tanaka N, Kudo S, Tabata M, Takeda K et al. (2008). Cytokine and chemokine expression in a rat endometriosis is similar to that in human endometriosis. Cytokine 43: 105-109.
40. Wang SB, Hu KM, Seamon KJ, Mani V, Chen Y, Gronert K (2012). Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J 26: 1506-1516.
41. Wu MY, Ho HN (2003). The role of cytokines in endometriosis. Am J Reprod Immunol 49: 285-296.
42. Wu SH, Liao PY, Dong L, Chen ZQ (2008). Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm Res 57: 430-437.
43. Xu Z, Zhao F, Lin F, Chen J, Huang Y (2012). Lipoxin A4 inhibits the development of endometriosis in mice: the role of anti-inflammation and anti-Angiogenesis. Am J Reprod Immunol 67: 491-497.
44. Y oshino O, Osuga Y, Koga K, Hirota Y, Hirata T, Ruimeng X et al. (2006). FR 167653, a p38 mitogen-Activated protein kinase inhibitor, suppresses the development of endometriosis in a murine model. J Reprod Immunol 72: 85-93.
45. Zhou WD, Yang HM, Wang Q, Su DY, Liu FA, Zhao M et al. (2010). SB203580, a p38 mitogen-Activated protein kinase inhibitor, suppresses the development of endometriosis by down-regulating proinfl ammatory cytokines and proteolytic factors in a mouse model. Hum Reprod 25: 3110-3116.
46. Zhou XY, Li YS, Wu P, Wang HM, Cai ZY, Xu FY et al. (2009). Lipoxin A(4) inhibited hepatocyte growth fa ctor-induced invasion of human hepatoma cells. Hepatol Res 39: 921-930.